A citation-based method for searching scientific literature

Leonid Barski, Tamar Eshkoli, Evgenia Brandstaetter, Alan Jotkowitz. Eur J Intern Med 2019
Times Cited: 27







List of co-cited articles
89 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
724
48

Euglycaemic diabetic ketoacidosis.
J F Munro, I W Campbell, A C McCuish, L J Duncan. Br Med J 1973
150
29

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
29


Euglycemic Diabetic Ketoacidosis: A Review.
Anar Modi, Abhinav Agrawal, Farah Morgan. Curr Diabetes Rev 2017
62
25

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
198
22

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale. Clin Ther 2016
99
22


Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
412
18

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
162
18

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Kelly R Burke, Christine A Schumacher, Spencer E Harpe. Pharmacotherapy 2017
84
18


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
18

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
72
14

ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.
Joseph I Wolfsdorf, Nicole Glaser, Michael Agus, Maria Fritsch, Ragnar Hanas, Arleta Rewers, Mark A Sperling, Ethel Codner. Pediatr Diabetes 2018
142
14

Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata, Takuya Haraguchi, Yoshiyuki Hamamoto, Takeshi Kurose, Kiminobu Sumita, Hitoshi Yamazato, Shigeto Kanada, Yutaka Seino. Diabetes Obes Metab 2017
44
14

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
14

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
14

Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature.
Pablo Lucero, Sebastián Chapela. Case Rep Crit Care 2018
15
26

Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.
Guillermo Umpierrez, Mary Korytkowski. Nat Rev Endocrinol 2016
132
11

Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014.
Stephen R Benoit, Yan Zhang, Linda S Geiss, Edward W Gregg, Ann Albright. MMWR Morb Mortal Wkly Rep 2018
80
11


Euglycaemic diabetic ketoacidosis: does it exist?
D Jenkins, C F Close, A J Krentz, M Nattrass, A D Wright. Acta Diabetol 1993
47
11

Risk of death following admission to a UK hospital with diabetic ketoacidosis.
Fraser W Gibb, Wei Leng Teoh, Joanne Graham, K Ann Lockman. Diabetologia 2016
50
11


Diabetic ketoacidosis in pregnancy.
Baha M Sibai, Oscar A Viteri. Obstet Gynecol 2014
32
11

Diabetic ketoacidosis: risk factors and management strategies.
Guillermo E Umpierrez, Abbas E Kitabchi. Treat Endocrinol 2003
83
11

Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Obes Metab 2018
38
11

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
11

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Gian Paolo Fadini, Benedetta Maria Bonora, Angelo Avogaro. Diabetologia 2017
95
11


Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication.
Asma Abu-Abed Abdin, Muhammad Hamza, Muhammad S Khan, Awab Ahmed. Case Rep Crit Care 2016
9
33

Starvation-induced true diabetic euglycemic ketoacidosis in severe depression.
Franklin Joseph, Lydia Anderson, Niru Goenka, Jiten Vora. J Gen Intern Med 2009
30
11

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
35
11

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
11



Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes.
Beate Karges, Joachim Rosenbauer, Paul-Martin Holterhus, Peter Beyer, Horst Seithe, Christian Vogel, Andreas Böckmann, Dirk Peters, Silvia Müther, Andreas Neu,[...]. Eur J Endocrinol 2015
47
7

CAUSES AND PREDICTORS FOR 30-DAY RE-ADMISSIONS IN ADULT PATIENTS WITH DIABETIC KETOACIDOSIS IN THE UNITED STATES: A NATIONWIDE ANALYSIS, 2010-2014.
Carolina R Hurtado, Alejandro Lemor, Franco Vallejo, Katherine Lopez, Rodrigo Garcia, Joseph Mathew, Rodolfo J Galindo. Endocr Pract 2019
7
28

An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois.
James A Mays, Kathryn L Jackson, Teresa A Derby, Jess J Behrens, Satyender Goel, Mark E Molitch, Abel N Kho, Amisha Wallia. Diabetes Care 2016
35
7

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
511
7

National survey of the management of Diabetic Ketoacidosis (DKA) in the UK in 2014.
K K Dhatariya, I Nunney, K Higgins, M J Sampson, G Iceton. Diabet Med 2016
48
7

Health Care Utilization and Burden of Diabetic Ketoacidosis in the U.S. Over the Past Decade: A Nationwide Analysis.
Dimpi Desai, Dhruv Mehta, Priyanka Mathias, Gopal Menon, Ulrich K Schubart. Diabetes Care 2018
50
7

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
87
7


Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
110
7


Guidelines for management of diabetic ketoacidosis: time to revise?
Ketan K Dhatariya, Guillermo E Umpierrez. Lancet Diabetes Endocrinol 2017
15
13

Risk Factors for Recurrent Diabetic Ketoacidosis in Adults With Type 1 Diabetes.
Sophie Del Degan, Frédérique Dubé, Claudia Gagnon, Geneviève Boulet. Can J Diabetes 2019
8
25

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
106
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.